AGTC to Present at Upcoming Virtual Conferences

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced its participation in two upcoming virtual conferences in October 2020. The first is the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, occurring from October 12-16, where CEO Sue Washer will present on-demand. The second event is the Dry AMD Therapeutic Development Summit on October 28-29, featuring CSO Mark Shearman in a panel discussion on dry AMD patient treatment. AGTC focuses on gene therapies for rare diseases, with clinical trials for inherited retinal diseases.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will participate in the following virtual conferences:

• Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (October 12-16, 2020)
  A company presentation by Sue Washer, President & Chief Executive Officer, will be available for registered attendees to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemesa.com for full information including registration.

• Dry AMD Therapeutic Development Summit (October 28-29, 2020)
  Mark Shearman, Chief Scientific Officer, will participate in a panel discussion titled “Defining the Therapeutic Journey for Dry AMD Patients”  at 9:15 a.m. ET on Wednesday, October 28, 2020. Please visit www.dry-amd-therapeutics.com for full information including registration.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

What is the date of AGTC's participation in the Cell & Gene Meeting on the Mesa?

AGTC will participate in the Cell & Gene Meeting on the Mesa from October 12-16, 2020.

Who will represent AGTC at the Dry AMD Therapeutic Development Summit?

Mark Shearman, the Chief Scientific Officer, will represent AGTC at the Dry AMD Therapeutic Development Summit.

What will Mark Shearman discuss at the Dry AMD Therapeutic Development Summit?

Mark Shearman will participate in a panel discussion titled 'Defining the Therapeutic Journey for Dry AMD Patients' on October 28, 2020.

What type of therapies does AGTC focus on?

AGTC focuses on developing adeno-associated virus (AAV) based gene therapies for rare inherited diseases.

What is the stock symbol for Applied Genetic Technologies Corporation?

The stock symbol for Applied Genetic Technologies Corporation is AGTC.